CN1511552A - Medicine for treating gastritis and peptic ulcer - Google Patents
Medicine for treating gastritis and peptic ulcer Download PDFInfo
- Publication number
- CN1511552A CN1511552A CNA021591970A CN02159197A CN1511552A CN 1511552 A CN1511552 A CN 1511552A CN A021591970 A CNA021591970 A CN A021591970A CN 02159197 A CN02159197 A CN 02159197A CN 1511552 A CN1511552 A CN 1511552A
- Authority
- CN
- China
- Prior art keywords
- rhizoma
- medicine
- gastric
- group
- water
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Granted
Links
- 239000003814 drug Substances 0.000 title claims abstract description 51
- 208000007882 Gastritis Diseases 0.000 title claims abstract description 23
- 208000008469 Peptic Ulcer Diseases 0.000 title claims abstract description 14
- 208000011906 peptic ulcer disease Diseases 0.000 title claims abstract description 14
- 229940079593 drug Drugs 0.000 title claims description 18
- 239000002775 capsule Substances 0.000 claims description 80
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 claims description 56
- LFQSCWFLJHTTHZ-UHFFFAOYSA-N Ethanol Chemical compound CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 claims description 37
- 239000007788 liquid Substances 0.000 claims description 28
- 241001619461 Poria <basidiomycete fungus> Species 0.000 claims description 16
- 239000010271 massa medicata fermentata Substances 0.000 claims description 16
- 239000000843 powder Substances 0.000 claims description 15
- 239000000284 extract Substances 0.000 claims description 13
- 230000006837 decompression Effects 0.000 claims description 9
- 238000001035 drying Methods 0.000 claims description 9
- 239000008187 granular material Substances 0.000 claims description 9
- 238000004064 recycling Methods 0.000 claims description 9
- 229920000858 Cyclodextrin Polymers 0.000 claims description 8
- 239000000706 filtrate Substances 0.000 claims description 8
- 239000000796 flavoring agent Substances 0.000 claims description 8
- 235000019634 flavors Nutrition 0.000 claims description 8
- 238000002360 preparation method Methods 0.000 claims description 8
- 239000000341 volatile oil Substances 0.000 claims description 8
- 238000000034 method Methods 0.000 claims description 7
- 239000002994 raw material Substances 0.000 claims description 7
- WHGYBXFWUBPSRW-FOUAGVGXSA-N beta-cyclodextrin Chemical compound OC[C@H]([C@H]([C@@H]([C@H]1O)O)O[C@H]2O[C@@H]([C@@H](O[C@H]3O[C@H](CO)[C@H]([C@@H]([C@H]3O)O)O[C@H]3O[C@H](CO)[C@H]([C@@H]([C@H]3O)O)O[C@H]3O[C@H](CO)[C@H]([C@@H]([C@H]3O)O)O[C@H]3O[C@H](CO)[C@H]([C@@H]([C@H]3O)O)O3)[C@H](O)[C@H]2O)CO)O[C@@H]1O[C@H]1[C@H](O)[C@@H](O)[C@@H]3O[C@@H]1CO WHGYBXFWUBPSRW-FOUAGVGXSA-N 0.000 claims description 6
- 235000011175 beta-cyclodextrine Nutrition 0.000 claims description 6
- 239000001116 FEMA 4028 Substances 0.000 claims description 5
- 229920002472 Starch Polymers 0.000 claims description 5
- 229960004853 betadex Drugs 0.000 claims description 5
- 239000008107 starch Substances 0.000 claims description 5
- 235000019698 starch Nutrition 0.000 claims description 5
- 239000006071 cream Substances 0.000 claims description 4
- 238000004821 distillation Methods 0.000 claims description 4
- 238000004321 preservation Methods 0.000 claims description 4
- 238000010992 reflux Methods 0.000 claims description 4
- 239000000203 mixture Substances 0.000 claims description 3
- 239000006187 pill Substances 0.000 claims description 3
- 239000002552 dosage form Substances 0.000 claims description 2
- 239000002674 ointment Substances 0.000 claims description 2
- 239000003826 tablet Substances 0.000 claims description 2
- 206010013786 Dry skin Diseases 0.000 claims 2
- 239000000084 colloidal system Substances 0.000 claims 2
- 230000002879 macerating effect Effects 0.000 claims 2
- 238000010298 pulverizing process Methods 0.000 claims 2
- 241000202807 Glycyrrhiza Species 0.000 claims 1
- 241001078983 Tetradium ruticarpum Species 0.000 claims 1
- 210000002784 stomach Anatomy 0.000 abstract description 50
- 208000025865 Ulcer Diseases 0.000 abstract description 41
- 231100000397 ulcer Toxicity 0.000 abstract description 41
- 230000000694 effects Effects 0.000 abstract description 25
- 210000004051 gastric juice Anatomy 0.000 abstract description 20
- 230000001684 chronic effect Effects 0.000 abstract description 13
- 230000017531 blood circulation Effects 0.000 abstract description 9
- 208000002193 Pain Diseases 0.000 abstract description 7
- 230000036407 pain Effects 0.000 abstract description 7
- 230000002401 inhibitory effect Effects 0.000 abstract description 5
- 239000000463 material Substances 0.000 abstract description 2
- 241000132012 Atractylodes Species 0.000 abstract 1
- 241000037740 Coptis chinensis Species 0.000 abstract 1
- 102000035195 Peptidases Human genes 0.000 abstract 1
- 108091005804 Peptidases Proteins 0.000 abstract 1
- 241001522129 Pinellia Species 0.000 abstract 1
- 241000234314 Zingiber Species 0.000 abstract 1
- 235000006886 Zingiber officinale Nutrition 0.000 abstract 1
- 230000003042 antagnostic effect Effects 0.000 abstract 1
- 235000008397 ginger Nutrition 0.000 abstract 1
- 230000001737 promoting effect Effects 0.000 abstract 1
- 235000019833 protease Nutrition 0.000 abstract 1
- 208000012895 Gastric disease Diseases 0.000 description 56
- FAPWRFPIFSIZLT-UHFFFAOYSA-M Sodium chloride Chemical compound [Na+].[Cl-] FAPWRFPIFSIZLT-UHFFFAOYSA-M 0.000 description 41
- QTBSBXVTEAMEQO-UHFFFAOYSA-N Acetic acid Chemical compound CC(O)=O QTBSBXVTEAMEQO-UHFFFAOYSA-N 0.000 description 36
- 241000700159 Rattus Species 0.000 description 31
- 235000003143 Panax notoginseng Nutrition 0.000 description 28
- 241000180649 Panax notoginseng Species 0.000 description 28
- 230000002496 gastric effect Effects 0.000 description 24
- 238000012360 testing method Methods 0.000 description 22
- 206010000087 Abdominal pain upper Diseases 0.000 description 17
- 210000001187 pylorus Anatomy 0.000 description 17
- 102000057297 Pepsin A Human genes 0.000 description 16
- 108090000284 Pepsin A Proteins 0.000 description 16
- 229940111202 pepsin Drugs 0.000 description 16
- 241000699670 Mus sp. Species 0.000 description 14
- 241001465754 Metazoa Species 0.000 description 11
- RTZKZFJDLAIYFH-UHFFFAOYSA-N Diethyl ether Chemical compound CCOCC RTZKZFJDLAIYFH-UHFFFAOYSA-N 0.000 description 10
- 235000019441 ethanol Nutrition 0.000 description 10
- 210000001156 gastric mucosa Anatomy 0.000 description 10
- 210000003097 mucus Anatomy 0.000 description 10
- 241000590002 Helicobacter pylori Species 0.000 description 9
- HEMHJVSKTPXQMS-UHFFFAOYSA-M Sodium hydroxide Chemical compound [OH-].[Na+] HEMHJVSKTPXQMS-UHFFFAOYSA-M 0.000 description 9
- 229940037467 helicobacter pylori Drugs 0.000 description 9
- 208000000114 Pain Threshold Diseases 0.000 description 8
- 230000037040 pain threshold Effects 0.000 description 8
- 201000010099 disease Diseases 0.000 description 7
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 description 7
- STZCRXQWRGQSJD-GEEYTBSJSA-M methyl orange Chemical compound [Na+].C1=CC(N(C)C)=CC=C1\N=N\C1=CC=C(S([O-])(=O)=O)C=C1 STZCRXQWRGQSJD-GEEYTBSJSA-M 0.000 description 7
- 229940012189 methyl orange Drugs 0.000 description 7
- WSFSSNUMVMOOMR-UHFFFAOYSA-N Formaldehyde Chemical compound O=C WSFSSNUMVMOOMR-UHFFFAOYSA-N 0.000 description 6
- 208000007107 Stomach Ulcer Diseases 0.000 description 6
- 230000037396 body weight Effects 0.000 description 6
- 201000005917 gastric ulcer Diseases 0.000 description 6
- DNXIKVLOVZVMQF-UHFFFAOYSA-N (3beta,16beta,17alpha,18beta,20alpha)-17-hydroxy-11-methoxy-18-[(3,4,5-trimethoxybenzoyl)oxy]-yohimban-16-carboxylic acid, methyl ester Natural products C1C2CN3CCC(C4=CC=C(OC)C=C4N4)=C4C3CC2C(C(=O)OC)C(O)C1OC(=O)C1=CC(OC)=C(OC)C(OC)=C1 DNXIKVLOVZVMQF-UHFFFAOYSA-N 0.000 description 5
- 241000700157 Rattus norvegicus Species 0.000 description 5
- LCQMZZCPPSWADO-UHFFFAOYSA-N Reserpilin Natural products COC(=O)C1COCC2CN3CCc4c([nH]c5cc(OC)c(OC)cc45)C3CC12 LCQMZZCPPSWADO-UHFFFAOYSA-N 0.000 description 5
- QEVHRUUCFGRFIF-SFWBKIHZSA-N Reserpine Natural products O=C(OC)[C@@H]1[C@H](OC)[C@H](OC(=O)c2cc(OC)c(OC)c(OC)c2)C[C@H]2[C@@H]1C[C@H]1N(C2)CCc2c3c([nH]c12)cc(OC)cc3 QEVHRUUCFGRFIF-SFWBKIHZSA-N 0.000 description 5
- 210000000683 abdominal cavity Anatomy 0.000 description 5
- 230000003187 abdominal effect Effects 0.000 description 5
- 230000001580 bacterial effect Effects 0.000 description 5
- 210000002318 cardia Anatomy 0.000 description 5
- 208000023652 chronic gastritis Diseases 0.000 description 5
- 230000034994 death Effects 0.000 description 5
- 239000000835 fiber Substances 0.000 description 5
- 230000012010 growth Effects 0.000 description 5
- 239000002609 medium Substances 0.000 description 5
- 230000003287 optical effect Effects 0.000 description 5
- BJOIZNZVOZKDIG-MDEJGZGSSA-N reserpine Chemical compound O([C@H]1[C@@H]([C@H]([C@H]2C[C@@H]3C4=C([C]5C=CC(OC)=CC5=N4)CCN3C[C@H]2C1)C(=O)OC)OC)C(=O)C1=CC(OC)=C(OC)C(OC)=C1 BJOIZNZVOZKDIG-MDEJGZGSSA-N 0.000 description 5
- 229960003147 reserpine Drugs 0.000 description 5
- MDMGHDFNKNZPAU-UHFFFAOYSA-N roserpine Natural products C1C2CN3CCC(C4=CC=C(OC)C=C4N4)=C4C3CC2C(OC(C)=O)C(OC)C1OC(=O)C1=CC(OC)=C(OC)C(OC)=C1 MDMGHDFNKNZPAU-UHFFFAOYSA-N 0.000 description 5
- 239000000243 solution Substances 0.000 description 5
- 208000024891 symptom Diseases 0.000 description 5
- -1 Dichlorodiphenyl Acetate Chemical compound 0.000 description 4
- 241000589989 Helicobacter Species 0.000 description 4
- 206010042220 Stress ulcer Diseases 0.000 description 4
- 208000000718 duodenal ulcer Diseases 0.000 description 4
- 238000011010 flushing procedure Methods 0.000 description 4
- 210000004877 mucosa Anatomy 0.000 description 4
- 208000037920 primary disease Diseases 0.000 description 4
- 241000699666 Mus <mouse, genus> Species 0.000 description 3
- 206010000269 abscess Diseases 0.000 description 3
- 230000036592 analgesia Effects 0.000 description 3
- 239000003153 chemical reaction reagent Substances 0.000 description 3
- 208000016644 chronic atrophic gastritis Diseases 0.000 description 3
- 239000012153 distilled water Substances 0.000 description 3
- 230000002183 duodenal effect Effects 0.000 description 3
- 235000013305 food Nutrition 0.000 description 3
- 238000001802 infusion Methods 0.000 description 3
- 230000028327 secretion Effects 0.000 description 3
- 210000000952 spleen Anatomy 0.000 description 3
- 241000894006 Bacteria Species 0.000 description 2
- OKTJSMMVPCPJKN-UHFFFAOYSA-N Carbon Chemical compound [C] OKTJSMMVPCPJKN-UHFFFAOYSA-N 0.000 description 2
- 238000012449 Kunming mouse Methods 0.000 description 2
- 206010067171 Regurgitation Diseases 0.000 description 2
- 208000005718 Stomach Neoplasms Diseases 0.000 description 2
- 210000001015 abdomen Anatomy 0.000 description 2
- 239000002253 acid Substances 0.000 description 2
- 230000001476 alcoholic effect Effects 0.000 description 2
- 230000000202 analgesic effect Effects 0.000 description 2
- 230000008485 antagonism Effects 0.000 description 2
- 238000011161 development Methods 0.000 description 2
- 230000018109 developmental process Effects 0.000 description 2
- 238000010790 dilution Methods 0.000 description 2
- 239000012895 dilution Substances 0.000 description 2
- 238000002474 experimental method Methods 0.000 description 2
- 206010017758 gastric cancer Diseases 0.000 description 2
- 230000030136 gastric emptying Effects 0.000 description 2
- 238000002347 injection Methods 0.000 description 2
- 239000007924 injection Substances 0.000 description 2
- 230000009545 invasion Effects 0.000 description 2
- 230000003902 lesion Effects 0.000 description 2
- 206010025482 malaise Diseases 0.000 description 2
- 230000004089 microcirculation Effects 0.000 description 2
- 229910052760 oxygen Inorganic materials 0.000 description 2
- 230000001681 protective effect Effects 0.000 description 2
- 230000009467 reduction Effects 0.000 description 2
- 238000011160 research Methods 0.000 description 2
- 230000000630 rising effect Effects 0.000 description 2
- HFHDHCJBZVLPGP-UHFFFAOYSA-N schardinger α-dextrin Chemical compound O1C(C(C2O)O)C(CO)OC2OC(C(C2O)O)C(CO)OC2OC(C(C2O)O)C(CO)OC2OC(C(O)C2O)C(CO)OC2OC(C(C2O)O)C(CO)OC2OC2C(O)C(O)C1OC2CO HFHDHCJBZVLPGP-UHFFFAOYSA-N 0.000 description 2
- FHHPUSMSKHSNKW-SMOYURAASA-M sodium deoxycholate Chemical compound [Na+].C([C@H]1CC2)[C@H](O)CC[C@]1(C)[C@@H]1[C@@H]2[C@@H]2CC[C@H]([C@@H](CCC([O-])=O)C)[C@@]2(C)[C@@H](O)C1 FHHPUSMSKHSNKW-SMOYURAASA-M 0.000 description 2
- 239000002689 soil Substances 0.000 description 2
- 230000000638 stimulation Effects 0.000 description 2
- 201000011549 stomach cancer Diseases 0.000 description 2
- 238000004448 titration Methods 0.000 description 2
- 210000002417 xiphoid bone Anatomy 0.000 description 2
- 229920001817 Agar Polymers 0.000 description 1
- 208000004300 Atrophic Gastritis Diseases 0.000 description 1
- 241000589562 Brucella Species 0.000 description 1
- 206010009866 Cold sweat Diseases 0.000 description 1
- 229920000742 Cotton Polymers 0.000 description 1
- 206010058314 Dysplasia Diseases 0.000 description 1
- 208000036495 Gastritis atrophic Diseases 0.000 description 1
- 208000032843 Hemorrhage Diseases 0.000 description 1
- 206010022998 Irritability Diseases 0.000 description 1
- 206010054949 Metaplasia Diseases 0.000 description 1
- 241000283898 Ovis Species 0.000 description 1
- 235000003140 Panax quinquefolius Nutrition 0.000 description 1
- 240000005373 Panax quinquefolius Species 0.000 description 1
- 239000004698 Polyethylene Substances 0.000 description 1
- 108010046334 Urease Proteins 0.000 description 1
- 230000001154 acute effect Effects 0.000 description 1
- 239000008272 agar Substances 0.000 description 1
- 238000001838 alkalimetric titration Methods 0.000 description 1
- 238000004458 analytical method Methods 0.000 description 1
- 238000010171 animal model Methods 0.000 description 1
- 230000003616 anti-epidemic effect Effects 0.000 description 1
- QVGXLLKOCUKJST-UHFFFAOYSA-N atomic oxygen Chemical compound [O] QVGXLLKOCUKJST-UHFFFAOYSA-N 0.000 description 1
- 244000052616 bacterial pathogen Species 0.000 description 1
- 230000003385 bacteriostatic effect Effects 0.000 description 1
- 230000008901 benefit Effects 0.000 description 1
- 239000008280 blood Substances 0.000 description 1
- 210000004369 blood Anatomy 0.000 description 1
- FPPNZSSZRUTDAP-UWFZAAFLSA-N carbenicillin Chemical compound N([C@H]1[C@H]2SC([C@@H](N2C1=O)C(O)=O)(C)C)C(=O)C(C(O)=O)C1=CC=CC=C1 FPPNZSSZRUTDAP-UWFZAAFLSA-N 0.000 description 1
- 229960003669 carbenicillin Drugs 0.000 description 1
- 238000006243 chemical reaction Methods 0.000 description 1
- 239000003795 chemical substances by application Substances 0.000 description 1
- 229940126678 chinese medicines Drugs 0.000 description 1
- 239000012531 culture fluid Substances 0.000 description 1
- 206010061428 decreased appetite Diseases 0.000 description 1
- 230000001079 digestive effect Effects 0.000 description 1
- 210000002249 digestive system Anatomy 0.000 description 1
- 208000010643 digestive system disease Diseases 0.000 description 1
- 238000007865 diluting Methods 0.000 description 1
- 230000035622 drinking Effects 0.000 description 1
- 230000000857 drug effect Effects 0.000 description 1
- 210000001198 duodenum Anatomy 0.000 description 1
- 239000000975 dye Substances 0.000 description 1
- 238000005516 engineering process Methods 0.000 description 1
- 230000002349 favourable effect Effects 0.000 description 1
- 230000006870 function Effects 0.000 description 1
- 210000004211 gastric acid Anatomy 0.000 description 1
- 210000004907 gland Anatomy 0.000 description 1
- PCHJSUWPFVWCPO-UHFFFAOYSA-N gold Chemical compound [Au] PCHJSUWPFVWCPO-UHFFFAOYSA-N 0.000 description 1
- 239000010931 gold Substances 0.000 description 1
- 229910052737 gold Inorganic materials 0.000 description 1
- 239000001963 growth medium Substances 0.000 description 1
- 235000012907 honey Nutrition 0.000 description 1
- 230000007062 hydrolysis Effects 0.000 description 1
- 238000006460 hydrolysis reaction Methods 0.000 description 1
- 208000015181 infectious disease Diseases 0.000 description 1
- 238000011081 inoculation Methods 0.000 description 1
- 230000000968 intestinal effect Effects 0.000 description 1
- 230000033001 locomotion Effects 0.000 description 1
- 230000015689 metaplastic ossification Effects 0.000 description 1
- VAOCPAMSLUNLGC-UHFFFAOYSA-N metronidazole Chemical compound CC1=NC=C([N+]([O-])=O)N1CCO VAOCPAMSLUNLGC-UHFFFAOYSA-N 0.000 description 1
- 229960000282 metronidazole Drugs 0.000 description 1
- 239000013642 negative control Substances 0.000 description 1
- 235000015097 nutrients Nutrition 0.000 description 1
- 210000000056 organ Anatomy 0.000 description 1
- 239000001301 oxygen Substances 0.000 description 1
- 230000008506 pathogenesis Effects 0.000 description 1
- 230000001717 pathogenic effect Effects 0.000 description 1
- 230000007170 pathology Effects 0.000 description 1
- 239000008188 pellet Substances 0.000 description 1
- 239000000546 pharmaceutical excipient Substances 0.000 description 1
- 230000003285 pharmacodynamic effect Effects 0.000 description 1
- 238000005375 photometry Methods 0.000 description 1
- 239000002574 poison Substances 0.000 description 1
- 231100000614 poison Toxicity 0.000 description 1
- 229920000573 polyethylene Polymers 0.000 description 1
- 239000013641 positive control Substances 0.000 description 1
- 229940126532 prescription medicine Drugs 0.000 description 1
- 230000002265 prevention Effects 0.000 description 1
- 238000011552 rat model Methods 0.000 description 1
- 230000000384 rearing effect Effects 0.000 description 1
- 230000010076 replication Effects 0.000 description 1
- 239000000523 sample Substances 0.000 description 1
- 230000011218 segmentation Effects 0.000 description 1
- 239000011734 sodium Substances 0.000 description 1
- 238000002415 sodium dodecyl sulfate polyacrylamide gel electrophoresis Methods 0.000 description 1
- STZCRXQWRGQSJD-UHFFFAOYSA-M sodium;4-[[4-(dimethylamino)phenyl]diazenyl]benzenesulfonate Chemical compound [Na+].C1=CC(N(C)C)=CC=C1N=NC1=CC=C(S([O-])(=O)=O)C=C1 STZCRXQWRGQSJD-UHFFFAOYSA-M 0.000 description 1
- 230000001954 sterilising effect Effects 0.000 description 1
- 238000004659 sterilization and disinfection Methods 0.000 description 1
- 238000005728 strengthening Methods 0.000 description 1
- 239000000126 substance Substances 0.000 description 1
- 239000006228 supernatant Substances 0.000 description 1
- 238000010998 test method Methods 0.000 description 1
- 230000001131 transforming effect Effects 0.000 description 1
- 230000032258 transport Effects 0.000 description 1
- 210000001835 viscera Anatomy 0.000 description 1
Landscapes
- Medicines Containing Plant Substances (AREA)
Abstract
The medicine for treating chronic superficial gastritis and peptic ulcer effectively is prepared with atractylodes rhizome, Chinese goldthread, dried orange peel, pinellia tuber, dry ginger and other five kinds of Chinese medicinal materials. It has obvious pain relieving effect, obvious antagonizing effect to various ulcers and the effects of lower acidity of gastric juice, lowering the activity of stomach proteinase and the amount of free stomach grume, increasing blood flow, promoting emptying stomach and inhibiting pyloric spirobacterium.
Description
Technical field
The present invention relates to a kind of medicine for the treatment of gastritis, peptic ulcer, especially for the medicine of treatment chronic superficial gastritis, peptic ulcer, belong to the field of Chinese medicines,
Background technology
Chronic superficial gastritis (CSG), peptic ulcer are a kind of commonly encountered diseases, the frequently-occurring diseases of digestive system, sickness rate ranks first in various digestive diseases, widespread usage along with gastroscope, its recall rate rises year by year, age is big more, sickness rate is high more, and the patient more than 40 years old more more sees that the male is more than the women.
Chronic superficial gastritis, peptic ulcer lack specific symptom, and the weight of clinical symptoms and the being seen lesion degree of gastroscope are often inconsistent.Primary disease is clinical often to show as the pain, glutted at the nearly pit of the stomach of gastral cavilty place, belch, and acid regurgitation, noisy, inappetence etc. belong to categories such as the traditional Chinese medical science " stomachache ", " feeling of fullness ", " acid regurgitation ", " noisy ".Chronic superficial gastritis cause of disease complexity, helicobacter pylori (Hp) are present clear and definite pathogenic bacterium, and the infection of Hp is to cause chronic gastritis to be shown effect repeatedly, the main cause that touching difficulty heals.Peptic ulcer is then many because of due to the gastroxia.Though the non-serious symptom of above-mentioned disease danger disease just because of difficult characteristics that heal repeatedly, is having a strong impact on the people's life, working and learning.
Doctor trained in Western medicine mainly is to eradicate Hp, and anti symptom treatment to such treatment of diseases at present, can improve symptom in a short time mostly, but easily recurrence, and certain side effect arranged, eradicate being extensive use of of Hp scheme in addition, the resistant rate of Hp constantly increases, there is data to show, Hp has reached 50% to the resistant rate of metronidazole, because with the passing of time primary disease can develop into chronic atrophic gastritis (CAG), and the intestinal epithelial metaplasia and the dysplasia that form on this basis are the precancerous lesions of gastric cancer, with the substantial connection that has of gastric cancer.Peptic ulcer then can cause perforation, hemorrhage, threat to life.Therefore, the research of further strengthening Chinese medicine prevention chronic superficial gastritis, peptic ulcer is imperative, can maximize favourable factors and minimize unfavourable ones, and improves curative effect.
Summary of the invention
The object of the invention provides a kind of medicine for the treatment of chronic superficial gastritis, peptic ulcer;
The present invention also provides the preparation method for the treatment of chronic superficial gastritis, digestive ulcer medicament.
The theoretical foundation of medicament composing prescription of the present invention is, chronic superficial gastritis, peptic ulcer belong to " gastric abscess " category, and the spleen body is cloudy and with sun, and is strong to be upgraded to, and leads fortuneization; Body of stomach sun and with cloudy, should fall then and, the main digesting food of being received, so-called " lunar wet soil, the positive beginning transports, Yang Mingyang soil; Cloudy beginning peace " (Ye Tianshi " Linzheng Zhinan Yi taste "), taste are barn organs, with placed in the middle burnt, hard and soft dryness and dampness coordinating each other, negative and positive are harmonious, department is received and is become thoroughly decomposed altogether, the duty of transporting and transforming nutrients from foodstuff is a pivot of rising and falling of QI.Right stomach internal organs communicates with the external world, is subject to most kill, and is said just as leaf sky scholar: " the lid stomach person converge also, is towards numerous thoroughfare, and is the easiest for suffering from " (" Linzheng Zhinan Yi gastric abscess ").If has a liking for the pungent delicious food of food, or sit the clammy ground that crouches, or feelings will is not smooth, depression of liver-QI, or being irritable and getting angry easily, irritability is crossed Sheng, and perverse and unreasonable manner takes advantage of spleen to violate stomach, or evil poison invasion and attack (being mainly Hp infects), or work and rest is excessive etc., all multifactor taste that all can injure, and taste are killd, fortuneization mistake department, endogenous dampness accumulates heat-transformation of a specified duration, resistance in damp and hot, spleen is the lucid yang sending up not, stomach-QI being unable to descend normally, stagnation of stomach-QI, stagnation of QI and blood may bring about pain begins into the disease of gastric abscess.Primary disease pathology character is real to mark, damp and hot middle resistance, and stagnation of stomach-QI is the pathogenesis key, controls when dampness heat clearing away, relieving QI stagnancy in the stomach.At the pathogenic characteristic of primary disease, treat the experience of superficial gastritis, peptic ulcer for many years in conjunction with the inventor, form prescription, be prepared into medicine, finished the present invention.
The raw material of preparation medicine of the present invention is formed as follows by weight:
Rhizoma Atractylodis 200-300 Rhizoma Coptidis 200-300 Pericarpium Citri Reticulatae 200-300 Rhizoma Pinelliae Preparatum 200-300
Rhizoma Zingiberis 100-200 Poria 200-300 Massa Medicata Fermentata 200-300 Fructus Evodiae 100-200
Fructus Amomi 100-200 Radix Glycyrrhizae 100-200
The raw material weight ratio of preparation medicine of the present invention is preferably:
Rhizoma Atractylodis 220-270 Rhizoma Coptidis 220-270 Pericarpium Citri Reticulatae 220-270 Rhizoma Pinelliae Preparatum 220-270
Rhizoma Zingiberis 130-180 Poria 130-180 Massa Medicata Fermentata 130-180 Fructus Evodiae 130-180
Fructus Amomi 130-180 Radix Glycyrrhizae 130-180
The raw material optimum weight ratio of preparation medicine of the present invention is:
Rhizoma Atractylodis 252g Rhizoma Coptidis 252g Pericarpium Citri Reticulatae 252g Rhizoma Pinelliae Preparatum 252g
Rhizoma Zingiberis 168g Poria 252g Massa Medicata Fermentata 252g Fructus Evodiae 168g
Fructus Amomi 168g Radix Glycyrrhizae 168g
The raw materials used Rhizoma Atractylodis of the present invention, Massa Medicata Fermentata preferably carry out parched with bran.
The above-mentioned prescription medicine of the present invention according to the preparation process of routine, can be prepared into pharmaceutical dosage form commonly used, for example, and pill, tablet, granule, oral liquid, unguentum, capsule, masticatory etc.
The preparation method of medicine capsule of the present invention is as follows:
(1) Radix Glycyrrhizae of taking-up 1/10 recipe quantity is ground into fine powder, crosses 100 mesh sieves, and is standby;
(2) get Fructus Amomi, Rhizoma Atractylodis, Rhizoma Zingiberis three flavor medicines, add 5-7 times of water gaging, extract volatile oil, collect.Get volatile oil, double his cyclodextrin, grind, drying, standby; Distillation gained water liquid filters, and medicinal residues add 5-7 times of water gaging again and decocted 20-50 minute, filter merging filtrate;
(3) get Rhizoma Coptidis, Rhizoma Pinelliae Preparatum, Fructus Evodiae three flavor medicines, add the ethanol that 5-7 doubly measures 70-85%, reflux, extract, 2-4 time, each 0.5-2 hour hour, merge extractive liquid,, decompression recycling ethanol (60～70 ℃ ,-0.08Mpa), get water liquid;
(4) get Pericarpium Citri Reticulatae, Poria, the Massa Medicata Fermentata Radix Glycyrrhizae, Poria, add 11-13 times of water gaging, decoct 1-2 time, each 0.5-2 hour, filter, collecting decoction, filtrate in gained medicinal liquid and the step (2) merges, and is concentrated into relative density and is about 1.08 (60 ℃), adds ethanol and makes and contain the alcohol amount and reach 40-60%, cold preservation 24 hours, filter, decompression recycling ethanol (60～70 ℃ ,-0.08Mpa), water liquid in gained water liquid and the step (3) merges, being evaporated to relative density is 1.32～1.35 (60 ℃), is blended into the Radix Glycyrrhizae fine powder in the step (1), (60～70 ℃ of drying under reduced pressure,-0.08Mpa), get dry extract;
(5) dried cream powder is broken, is blended into the betacyclodextrin clathrate in the step (2), and adds starch, and capsule charge is made 1000 of capsules altogether.
Medicine of the present invention has significant analgesia role, and ulcer due to stress ulcer, pyloric ligation ulcer, acetic acid ulcer and the reserpine is had tangible antagonism, can increase the gastric juice content of pylorus ligation rat, reduces the acidity of gastric juice; Reduce acidity and the ulcer area of acetic acid ulcer animal pattern; Improve chronic model gastritis rat stomach acidacidity, reduce pepsin activity and free stomach mucus amount; Increase the gastric mucosa blood flow; Promote the emptying of stomach; External have inhibitory action to helicobacter pylori.Can treat chronic superficial gastritis effectively.
Following pharmacodynamic experiment data has confirmed the above-mentioned medical function of medicine of the present invention.
Test material
Be subjected to the reagent thing
Title: the grey gastric disease Yiganning capsule extractum (trade name of medicine of the present invention) that connects.
The unit of providing: Jiangsu normal celestial movement medical sci-tech development company
Lot number: 20010103
Content: 200%, every milliliter contains the 2g crude drug
Designed by the configuration and the dosage of reagent thing: press the body surface area conversion, determine the high, medium and low 5.6g/kg of being respectively of rat crude drug amount, 2.8g/kg, 1.4g/kg, the administration volume is 1ml/100g.High, medium and low 2.8g/kg, 1.4g/kg, the 0.7g/kg of being respectively of mice crude drug amount, the administration volume is 0.2ml/10g, duodenal administration concentration is respectively 112%, 56%, 28%.
The contrast medicine: Guilin herbal pharmaceutical factory of Radix Notoginseng capsule for treating stomachache Guilin three gold medals (Pharmaceutical) group produces, lot number: 000358, become 10% (rat), 5% (mice) with distilled water diluting, the administration volume is respectively 1ml/100g, 0.2ml/10g, and dosage is equivalent to 10 times of clinical consumption.
Helicobacter pylorus strain: available from Shandong Prov. Sanitation and Antiepidemic Station, obtaining for helicobacter pylori patient gastric mucosa separates, through being accredited as domestic representational NCTC1163 strain, is the N93 type through the SDS-PAGE typing.
Other reagent: be analytical pure.
Experimental animal
Strain, source: kunming mouse, the WISTAR rat quality certification number: Shandong animal matter word 200001002,200001003.
Feedstuff: test Mus full-valence pellet feed, operative norm: GB19424-94.
Raise: the conventional raising, room temperature is controlled at 22-26 ℃
Test equipment
Mice hot plate pain instrument: the Academy of Medical Sciences, Shandong development.
JI-200 type laser-Doppler microcirculation kinetic analyzer: Tianjin Jin Ke electronic equip corporation and other instruments.
Test method and result
One, the grey gastric disease Yiganning capsule analgesic test that connects
1. the grey influence that connects the gastric disease Yiganning capsule to hot plate induced mice pain
Select female mice, body weight 18-22g, select the qualified mice of pain threshold (licking the metapedes time) (pain threshold is 5 seconds-30 seconds) at hot-plate instrument (55 ℃ of temperature), select 60 altogether, be divided into 5 groups at random, 12 every group according to pain threshold, the grey gastric disease Yiganning capsule and the Radix Notoginseng capsule for treating stomachache (hereinafter to be referred as Radix Notoginseng) of connecting of three dosage of difference gastric infusion, volume is all the normal saline of 0.2ml/10g and equating volume, and respectively at 30 minutes, 60 minutes mensuration mice pain thresholds after the administration, result of the test sees Table 1:
Table 1: the grey gastric disease Yiganning capsule that connects is to the influence of hot plate induced mice pain threshold (X ± SD)
60 minutes (second) after the administration 30 minutes (second) after (second) administration before the group administration
Normal saline group 18.67 ± 5.88 17 ± 7.14 19.75 ± 4.49
Small dose group 17.83 ± 7.07 21 ± 7.66 20.58 ± 7.17
Middle dosage group 18.00 ± 4.95 27.25 ± 10.23
△ ※27.83 ± 11.09
△
Heavy dose of group 18.92 ± 5.68 34.33 ± 15.38
△ △ ※32.5 ± 14.04
△
Radix Notoginseng group 18.92 ± 4.98 20.58 ± 6.27 24.75 ± 7.23
Compare than △ p＜0.05 with the normal saline group, △ △ p＜0.01, dosage, heavy dose can obviously prolong mice hot plate pain threshold in the grey even gastric disease Yiganning capsule, and Radix Notoginseng capsule for treating stomachache unknown significance difference; Compare ※ p＜0.05 with Radix Notoginseng capsule for treating stomachache group.
2. turn round the influence of body due to the grey even gastric disease Yiganning capsule Dichlorodiphenyl Acetate
Get 50 male and female half and half of Kunming mouse, be divided into 5 groups at random, every group 10, the grey normal saline that connects gastric disease Yiganning capsule, Radix Notoginseng capsule for treating stomachache and equating volume of large, medium and small three dosage of gastric infusion, every mouse peritoneal is injected 0.6% acetic acid 0.2ml behind the 45min, the record mice turn round for the first time occur in time that body occurs and the 20min turn round the body number of times, result of the test sees Table 2:
Table 2: the grey influence of turning round body due to the gastric disease Yiganning capsule Dichlorodiphenyl Acetate (X ± SD) that connects
Group is turned round for the first time in time (branch) 20min that body occurs and is turned round the body number of times
Normal saline group 3.5 ± 0.97 44 ± 9.72
Small dose group 7.6 ± 3.81
△ △32.4 ± 11.3
△
Middle dosage group 7.9 ± 3.86
△ △25.4 ± 7.71
△ △
Heavy dose of group 9.4 ± 2.91
△ △21.5 ± 5.5
△ △
Radix Notoginseng group 6.9 ± 2.88
△ △28 ± 11.4
△ △
Compare △ P＜0.05, △ △ P＜0.01 with the normal saline group
As can be seen from the table: writhing test due to the grey even gastric disease Yiganning capsule Dichlorodiphenyl Acetate, can obviously prolong and turn round the time that body occurs first, obviously reduce and turn round the body number of times in the 20min, compare there was no significant difference with the Radix Notoginseng capsule for treating stomachache.
The analgesic test shows: the grey gastric disease Yiganning capsule that connects can reduce the hot plate pain threshold of mice, and middle dosage, heavy dose and Radix Notoginseng capsule for treating stomachache relatively have significant difference (P＜0.05), and effect is better than the Radix Notoginseng capsule for treating stomachache; The pain that chemical stimulation is caused has significant analgesia role, turn round the body number of times in the 20min and the normal saline group relatively has significant difference, low dose of P＜0.05, middle dosage, heavy dose of P＜0.01, turning round time that body occurs first obviously prolongs low dose, middle dosage, heavy dose significant difference (P＜0.01) is all arranged, and greyly connects the gastric disease Yiganning capsule and the Radix Notoginseng capsule for treating stomachache compares there was no significant difference.The grey gastric disease capsule that connects of overall merit is better than the Radix Notoginseng capsule for treating stomachache.
Two, the grey influence that connects the gastric disease Yiganning capsule to gastric ulcer
1. the grey influence that connects the gastric disease Yiganning capsule to stress ulcer
Get 50 of WISTAR rats, body weight 190g-220g, male and female half and half, each is organized rat and all is placed in the cage of the no end, water 24h is can't help in fasting, it is big to irritate stomach respectively, in, the grey normal saline that connects gastric disease Yiganning capsule extractum and Radix Notoginseng capsule for treating stomachache and equating volume of little three dosage, volume is all 1ml/100g, with line rat was fixed on the rat fixing head in 45 minutes after the administration, and rat is dipped in 20 ℃ of water, water logging is to the rat xiphoid-process, put into water 10h after take out sacrificed by decapitation, ligation pylorus, cardia, and injection gastric 1% formaldehyde 10ml, the tailing edge greater gastric curvature was cut off in 10 minutes, waftd gently with clear water and washed, and pressed Qi Chen's " herbal pharmacology research methodology " ulcer level standard: I level＜1mm, II level: 1-3mm, III level＞3mm, record ulcer is counted and ulcer level, and result of the test sees Table 3:
Table 3: the grey gastric disease Yiganning capsule that connects is to the influence of stress ulcer (X ± SD)
The group ulcer ulcer level I level II level III level of counting
Normal saline group 16.9 ± 3.87 6.4 ± 3.24 4.4 ± 2.12 5.8 ± 1.87
Small dose group 14.1 ± 3.45 5.1 ± 2.02 4.3 ± 2.57 5.8 ± 1.93
Middle dosage group 12.7 ± 3.43
△4.7 ± 2.63 3.4 ± 1.51 4.9 ± 2.42
Heavy dose of group 12.4 ± 4.01
△6.1 ± 2.02 4.1 ± 1.29 4.1 ± 2.69
Radix Notoginseng group 10.0 ± 3.53
△ △6.1 ± 1.20 2.5 ± 1.72
△2.7 ± 1.42
△
Compare △ P＜0.05, △ △ P＜0.01 with the normal saline group
As can be seen from the table: the grey gastric disease Yiganning capsule that connects is to stress ulcer, with the normal saline group, the number (P＜0.05) of middle dosage, heavy dose of obviously minimizing rat gastric ulcer; Ulcer levels at different levels all there is the trend of alleviating, but statistics unknown significance difference, and Radix Notoginseng capsule for treating stomachache and the comparison of normal saline group have significant difference (P＜0.05) than II level, III level.
2. the grey influence that connects the gastric disease Yiganning capsule to pylorus ligation
Get 50 of wistar rats, body weight 190g-220g, male and female half and half, water 48h is can't help in fasting, and the shallow fiber crops of ether are fixed on the rat fixing head, under xiphoid-process, cut off the abdominal cavity and touch out stomach, the ligation pylorus, water 48h is can't help in fasting, the shallow fiber crops of ether, and from duodenal administration once, dosage 0.5ml/100g, stomach is put back to the abdominal cavity, sew up abdominal part, put to death rat behind the 10h, the ligation cardia, take out stomach, and inject gastric 1% formaldehyde 10ml, the tailing edge greater gastric curvature was cut off in 10 minutes, waftd gently with clear water and washed, record ulcer is counted and ulcer level, and result of the test sees Table 4:
Table 4: the grey gastric disease Yiganning capsule that connects is to the influence of pylorus ligation (X ± SD)
The group ulcer ulcer level I level II level III level of counting
Normal saline group 14.2 ± 4.8 7.1 ± 2.64 3.0 ± 2.88 4.0 ± 2.79
Small dose group 13.1 ± 4.09 7.1 ± 3.31 4.1 ± 2.69 1.9 ± 0.49
△ △
Middle dosage group 9.6 ± 3.41
△6.4 ± 1.84 2.1 ± 1.66 1.1 ± 0.99
△ △
Heavy dose of group 7.4 ± 3.84
△4.2 ± 1.75
△ △1.9 ± 0.99 1.0 ± 1.41
△ △
Radix Notoginseng group 8.2 ± 3.68
△6.5 ± 2.99 1.2 ± 1.23 0.5 ± 0.52
△ △
Compare than △ P＜0.05 △ △ P＜0.01 with the normal saline group
As can be seen from the table: dosage, heavy dose and normal saline group are in the grey even gastric disease Yiganning capsule, the ulcer number obviously reduces, significant difference (△ P＜0.05) is arranged, heavy dose all obviously alleviates (△ P＜0.05) to ulcer I level, III level, low dose of, middle dosage has obviously ulcer III level and alleviates, can alleviate the degree of pylorus ligation ulcer, particularly alleviate ulcer than the order of severity.
3. the grey influence that connects the gastric disease Yiganning capsule to ulcer due to the acetic acid
The rats acetic acid gastric ulcer model is with reference to okabc, the shallow fiber crops of 24h ether before the art, open abdominal part, stomach is drawn, and with the full gland division that is clipped in of acetic acid, the acetic acid 0.1ml with 50% injects in the annulus, treat to blot acetic acid in the ring with Cotton Gossypii after 60 seconds, take off full folder, use the normal saline flushing coat of the stomach, sew up coat of the stomach and stomach wall then, be divided into 5 groups every group 10 at random, it is big to irritate stomach respectively, in, the grey normal saline that connects gastric disease Yiganning capsule and Radix Notoginseng capsule for treating stomachache and equating volume of little three dosage, volume is all 1ml/100g, continuous 11 days, under the shallow fiber crops of ether, opened abdominal part on the 12nd day, in pylorus and the ligation of duodenum place, it is the polyethylene tube of 3mm that per os inserts diameter, inserts in the stomach always, inject the 4ml normal saline with syringe, and gastric content pumped, send stomach back to abdominal cavity then, sew up the incision.Put to death rat with etherization behind the 3h, the ligation cardia takes out whole stomach, measures the gastric juice amount, and with 0.1molNaOH titration gastric juice, calculates the acidity value (mmol/L) of gastric juice, and reference literature method mensuration pepsin activity (ug/ml/min).And measure and calculate π * (d
1/ 2) * (d
2/ 2) ulcer surface, π are pi, d
1, d
2Be vertical footpath of the maximum of ulcer surface and maximum transverse diameter.Result of the test sees Table 5,6.
Table 5: the grey gastric disease Yiganning capsule that connects is to the influence of ulcer due to the acetic acid (X ± SD)
Group number of animals ulcer area (mm
2)
Normal saline group 10 5.69 ± 0.95
Small dose group 10 4.64 ± 0.63
△
Middle dosage group 10 3.25 ± 0.42
△ △
Heavy dose of group 10 2.52 ± 0.23
△ △
Radix Notoginseng organizes 10 3.68 ± 0.31
△ △
Compare than △ △ P＜0.01 with the normal saline group, compare ※＜0.05 with the Radix Notoginseng capsule for treating stomachache
The grey gastric disease Yiganning capsule that connects is to ulcer due to the acetic acid: with the normal saline group relatively, area all obviously dwindles, and has significant difference (△ △ P＜0.01)
Table 6: the grey gastric disease Yiganning capsule that connects is to the excretory influence of rat gastric juice (X ± SD)
Group gastric juice amount (ml) acidity (mmol/L) pepsin activity (ug/ml/min)
Normal saline group 3.27 ± 0.66 7.3 ± 1.23 1.23 ± 0.22
Small dose group 3.12 ± 0.53 6.3 ± 1.43 1.21 ± 0.11
Middle dosage group 2.14 ± 0.51 6.1 ± 1.02
△1.08 ± 0.17
Heavy dose of group 2.26 ± 0.50
△5.2 ± 1.63
△ △1.15 ± 0.21
Radix Notoginseng group 3.17 ± 0.66 6.7 ± 1.79 1.20 ± 0.17
Compare than △ P＜0.05 △ △ P＜0.01 with the normal saline group
Greyly connect gastric disease Yiganning capsule and the comparison of normal saline group: middle dosage, heavy dose can significantly reduce gastric acidity (△ P＜0.05, △ △ P＜0.01), and pepsin activity is had reduction trend but statistics is not seen evident difference.Connect the gastric disease Yiganning capsule to ulcer test due to the acetic acid as can be seen from grey, the grey gastric disease capsule that connects can significantly reduce acidity, reduces the stimulation of gastric acid to gastric mucosa, and the protection gastric mucosa reduces pepsic activity, reduces the invasion and attack to gastric mucosa.
4. the grey influence that connects the gastric disease Yiganning capsule to ulcer due to the reserpine
Get 50 of wistAr rats, body weight 220g-240g, male and female half and half, every group 10, the emergent ulcer test of administration, continuous 4 days, the every Mus lumbar injection of 1h reserpine 5mg/kg after administration in the 3rd day, and water is can't help in fasting, behind the 4th day administration 5h, take off cervical vertebra and put to death rat, observational technique is with emergent ulcer test, the degree of record rat gastric ulcer, result of the test sees Table 7:
Table 7: the grey gastric disease Yiganning capsule that connects is to the influence of ulcer due to the reserpine (X ± SD)
The group ulcer ulcer level I level II level III level of counting
Normal saline group 18.4 ± 3.86 10.3 ± 3.92 4.7 ± 1.34 3.4 ± 1.53
Small dose group 16.7 ± 2.06 10.2 ± 3.01 3.9 ± 1.52 2.6 ± 0.98
Middle dosage group 13.9 ± 2.69
△ △9.1 ± 2.47 2.1 ± 0.99
△ △2.7 ± 1.22
Heavy dose of group 11.8 ± 3.82
△ △8.9 ± 2.77 1.7 ± 1.06
△ △1.2 ± 0.46
△ △
Radix Notoginseng group 13.1 ± 3.13
△ △8.4 ± 3.03 2.5 ± 0.85
△ △2.2 ± 0.79
△
Compare than △ P＜0.05 △ △ P＜0.01 with the normal saline group
Dosage, the heavy dose of ulcer number is obviously reduced with the normal saline group relatively have significant difference (△ △ P＜0.01) in the grey as can be seen from the table even gastric disease Yiganning capsule, in dosage, heavy dose of ulcer II level is all obviously alleviated, heavy dose of ulcer III level is had obviously alleviate.Dosage is bigger, and the effect of protection gastric mucosa is stronger.
Three, the grey influence that connects the gastric disease Yiganning capsule to rat pylorus ligation gastric secretion
Get 50 of wistar rats, body weight 190g-220g, male and female half and half, water 48h is can't help in fasting, and the shallow fiber crops of ether are cut off the abdominal cavity and touch out stomach, the ligation pylorus, and from duodenal administration once, dosage 0.5ml/100g puts back to the abdominal cavity with stomach, sew up abdominal part, put to death rat behind the 10h, the ligation cardia takes out stomach, measure the gastric juice amount, get 1ml gastric juice with the alkalimetric titration Both of gastric acidity, calculate the acidity value (mmol/L) of gastric juice, and measure pepsin activity according to the NaOH consumption, measure the OD value at the 660nm wavelength, reference literature calculates pepsin activity according to standard curve, pepsin activity (u/ml)=mensuration pipe (OD)/control tube (OD) * 1.47, and result of the test sees Table 8:
Table 8: the grey gastric disease Yiganning capsule that connects is to the excretory influence of rat gastric juice (X ± SD)
Group gastric juice amount (ml) acidity (mmol/L) pepsin activity (u/ml)
Normal saline group 6.27 ± 2.25 8.3 ± 3.33 1.65 ± 0.32
Small dose group 6.6 ± 2.23 7.3 ± 2.41 1.31 ± 0.69
Middle dosage group 8.34 ± 2.51 5.1 ± 1.37
△1.56 ± 0.60
Heavy dose of group 9.75 ± 2.50
△4.2 ± 2.36
△ △1.49 ± 0.44
Radix Notoginseng group 7.17 ± 2.66 7.7 ± 2.75 1.61 ± 0.65
Compare △ P＜0.05, △ △ P＜0.01 with the normal saline group
The grey gastric disease Yiganning capsule that connects compares with the normal saline group acute pylorus ligation, and gastric secretion can increase, and heavy dose of group relatively has significant difference (△ P＜0.05) with it; To gastric secretion: with the normal saline group relatively, the grey gastric disease Yiganning capsule that connects obviously reduces Both of gastric acidity, middle dosage, heavy dose of and normal saline group relatively have significant difference (△ P＜0.05, △ △ P＜0.01).Little to the pepsin influence.
Four, the grey influence that connects the gastric disease Yiganning capsule to the chronic gastritis model
Male and female rat sub-cage rearing, 5 in every cage, except that normal group each treated animal at first month every five days, gavaged 60% alcoholic solution once every seven days in the second month, each every 2ml, therebetween with pH7.0-7.8, the deoxycholic acid sodium solution of 20mmol/L replaces water and arbitrarily drinks.Then used 30% alcoholic solution and 20mmol/L deoxycholic acid sodium solution in three month respectively,, once arbitrarily drink by turns every three days.Continuous 90 days, treatment group rat gavaged large, medium and small grey gastric disease Yiganning capsule and the equating volume normal saline of connecting respectively, and once a day, each 2ml continues 30 days, normal group animal drinking public water supply.During off-test, water 16h is can't help in each animal fasting, with the animal sacrificed by decapitation, cut open the belly immediately ligation cardia and pylorus, win full stomach,, gastric juice is carried out gastric analysis with 5ml distilled water flushing gastral cavity, use the titration of 0.01mol/LNaOH solution to PH7.0 1ml stomach flushing liquor, color occurs till the pink, and record consumes the NaOH amount, calculates the acidity value (mmol/L) of gastric juice according to the NaOH consumption; Get the gastric juice 1ml of 10 times of dilutions, reference literature is pressed hydrolysis and is measured pepsin activity (u/ml), the free mucus content (mg) of gastric juice.Result of the test sees Table 9:
Table 9: the grey gastric disease Yiganning capsule that connects is to the influence of chronic model gastritis rat gastric juice composition (X ± SD)
Group acidity (mmol/L) pepsin activity (u/ml) the mucus content (mg) that dissociates
Normal group 5.5 ± 1.1 0.97 ± 0.29 0.51 ± 0.11
Model group 4.1 ± 0.33
※ ※1.50 ± 0.35
※ ※0.74 ± 0.09
※ ※
Small dose group 4.3 ± 0.63
※ ※1.38 ± 0.41
※0.69 ± 0.12
※ ※
Middle dosage group 5.1 ± 0.97
△1.21 ± 0.91 0.62 ± 0.10
△ ※
Heavy dose of group 5.3 ± 1.2
△0.91 ± 0.35
△ △0.53 ± 0.13
△ △
Radix Notoginseng group 4.9 ± 0.56 1.32 ± 0.43
※0.61 ± 0.13
With model group than △ P＜0.05, △ △ P＜0.01 is with normal group ※ P＜0.05 relatively, ※ P ※＜0.01
Compare with normal group, the model group Both of gastric acidity obviously reduces, and pepsin activity obviously raises, and free stomach mucus content significantly raises, and model group and normal saline group relatively have evident difference; Low dose of and normal group comparison Both of gastric acidity significantly reduces; pepsin activity obviously raises; free stomach mucus content significantly raises; middle dosage has only free stomach mucus content that rising is arranged, and other do not see notable difference; and heavy dose compares Both of gastric acidity with normal group; pepsin activity; free stomach mucus content is not all seen notable difference; with dosage in the more grey even gastric disease Yiganning capsule of model group; heavy dose of Both of gastric acidity (△ P＜0.05) that can increase the chronic gastritis rat model; reduce free stomach mucus content; the grey gastric disease Yiganning capsule heavy dose that connects can obviously reduce pepsin activity, and chronic gastritis is had significant protective effect.
Five, the grey influence that connects the gastric disease Yiganning capsule to rat stomach mucosa blood flow
The grouping administration is with experiment 2, and water is can't help in administration fasting in the 4th day, and be administered once the 5th day morning, treat 2h after, with JI-200 type laser-Doppler microcirculation kinetic analyzer, survey gastric mucosa blood flow (GMBF).Measuring method: animal with etherization after, be fixed on the platform, be 37 ℃ of calorstats under the platform, to keep rat temperature.In last median abdominal incision, incision length is about 1.5cm, gently proposes stomach, cuts the otch of a 0.2cm in the greater gastric curvature side, after 37 ℃ of normal saline flushing stomaches, the miniature laser probe is put into body of stomach from otch, measure GMBF, continue 1 minute, record blood flow numerical value, 5 minutes replications 2 times more at interval, its average the results are shown in Table 10 as rat stomach mucosa blood flow:
Table 10: the grey gastric disease Yiganning capsule that connects is to the influence of rat stomach mucosa blood flow (X ± SD)
Group number of animals gastric mucosa blood flow (GMBF)
Normal saline group 10 30.2 ± 3.3
Small dose group 10 32.7 ± 3.46
Middle dosage group 10 35.9 ± 3.47
△ △
Heavy dose of group 10 39.7 ± 4.14
△ △
Radix Notoginseng organizes 10 30.5 ± 2.62
Compare △ P＜0.01 with the normal saline group, dosage, heavy dose can increase rat stomach mucosa blood flow in the grey even gastric disease Yiganning capsule.
Six, the grey influence that connects the gastric disease Yiganning capsule to gastric emptying
Get 50 of the mices of body weight 18-22g, male and female half and half are divided into 5 groups at random, grey large, medium and small three dosage of gastric disease Yiganning capsule that connect of difference gastric infusion, Radix Notoginseng capsule for treating stomachache, normal saline 0.2ml/10g, once a day, continuous three days, give with medicine (to reduce the influence of color) in last with activated carbon decolorizing, behind the 2h, 0.1% methyl orange solution of every oral 0.2ml of animal takes off cervical vertebra and puts to death animal after 20 minutes after the administration, cut open the belly and get gastric content, use Na
2CO
3Regulate PH to 8.5, pour in the centrifuge tube, 2000 leave the heart got supernatant in 10 minutes in 721 type spectrophotometers (wavelength 420nm) photometry density, and add the optical density that records in the 10ml distilled water as radix methyl orange optical density with 0.1% methyl orange 0.2ml, and press following formula and calculate methyl orange stomach residual rate: methyl orange optical density in methyl orange stomach residual rate=stomach/radix methyl orange optical density * 100%, result of the test sees Table 11:
Table 11: the grey gastric disease Yiganning capsule that connects is to the influence of gastric emptying (X ± SD)
The residual methyl orange optical density of group stomach residual rate (%)
Normal saline group 0.338 ± 0.04 75
Small dose group 0.326 ± 0.06 72
Middle dosage group 0.314 ± 0.04 70
Heavy dose of group 0.223 ± 0.03
△50
Radix Notoginseng group 0.316 ± 0.05 70
Compare △ P＜0.05 with the normal saline group; Grey even gastric disease Yiganning capsule heavy dose can increase the emptying of rat stomach.
Six, the grey external helicobacter pylori that presses down of gastric disease Yiganning capsule that connects is tested
A peek culture dish adds brucella agar culture medium+10% Sanguis caprae seu ovis.Drug level adopts doubling dilution from 0.5g/ml, and concentration is respectively 0.5g/ml, 0.25g/ml, 0.125g/ml, 0.0625g/ml, 0.0312g/ml, 0.0156g/ml, and every culture dish adds helicobacter pylorus strain (N
93) (every ml contains 10 to 1ml
3Individual helicobacter pylori, this bacterial strain is taken from the gastric mucosa culture fluid through the male gastric ulcer patient of urease check helicobacter pylori), the filter paper of cut-off footpath 6mm dips in the medicinal liquid of getting variable concentrations respectively and puts into culture dish, 6 filter papers of every kind of concentration inoculation, adopt sxemiquantitative to judge drug effect ,=for the scraps of paper do not have bacterial growth on every side ,+be the minority colony growth, ++ be a plurality of colony growths around the scraps of paper, +++for intensive colony growth in heaps is arranged around the scraps of paper.Culture dish is at 37 ℃ of temperature, 5%O
2Little oxygen condition is cultivated down 72h, observe to have or not the helicobacter pylorus bacteria growing, and smear dyes with Gram, checks to have or not helicobacter pylori under oily mirror, and helicobacter pylori is curved, S shape or sea-gull spread the wings shape.Make positive control drug with carbenicillin, to dip in the negative control of normal saline as bacterial strain.The drug level of the filter paper of no helicobacter pylorus bacteria growing is as the grey minimum inhibitory concentration that connects the gastric disease Yiganning capsule, and result of the test sees Table 12:
Table 12: the grey gastric disease Yiganning capsule bacteriostatic test result that connects
Grey gastric disease Yiganning capsule concentration (g/ml) the bacterial strain medicine that connects
0.5 0.25 0.125 0.0625 0.0312 0.0156 contrast contrast
＝ ＝ ＝ ＝ + ++ +++ ＝
Annotate: "=" six repeats all aseptic length of being born of filter paper; "+~ +++" the bacterial growth degree.As can be seen from the table, grey even gastric disease Yiganning capsule minimum inhibitory concentration is 0.0625g/ml.
From test as can be seen, the grey gastric disease Yiganning capsule that connects has significant analgesia role, reduces the acetic acid induced mice and turns round the body number of times, prolongs the time that occurs turning round body first, improves the mice pain threshold, and the grey gastric disease capsule curative effect that connects is better than the Radix Notoginseng capsule for treating stomachache; Ulcer due to straining lasering type, pylorus ligation ulcer and the reserpine there is tangible antagonism, reduces gastric ulcer degree and ulcer area; Can increase the gastric juice content of pylorus ligation rat, the acidity of reduction gastric juice, reduce and travel stomach mucus content, gastric mucosa is had significant protective effect; Improve chronic model gastritis rat stomach acidacidity, reduce pepsin activity and stomach mucus amount, help chronic gastritis, particularly the treatment of atrophic gastritis; The grey gastric disease Yiganning capsule heavy dose that connects has the emptying that promotes stomach, helps the alleviation of pain; External have inhibitory action to helicobacter pylori.
Preferred forms
Embodiment 1
Rhizoma Atractylodis 200g Rhizoma Coptidis 200g Pericarpium Citri Reticulatae 200g Rhizoma Pinelliae Preparatum 200g Rhizoma Zingiberis 100g
Poria 200g Massa Medicata Fermentata 200g Fructus Evodiae 100g Fructus Amomi 100g Radix Glycyrrhizae 100g
The above-mentioned raw materials medicine is decocted with water twice, and amount of water is 8 times for the first time, heats 1 hour, and amount of water is 6 times for the second time, heats half an hour, merges decoction liquor twice, filters, and is condensed into dry extract, pulverizes, and sieves, and makes granule.
Embodiment 2
Rhizoma Atractylodis 300g Rhizoma Coptidis 300g Pericarpium Citri Reticulatae 300g Rhizoma Pinelliae Preparatum 300g Rhizoma Zingiberis 200g
Poria 300g Massa Medicata Fermentata 300g Fructus Evodiae 200g Fructus Amomi 200g Radix Glycyrrhizae 200g
Said medicine is ground into segmentation, crosses 100 mesh sieves, adds refined honey, makes honeyed pill.
Embodiment 3
Rhizoma Atractylodis 220g Rhizoma Coptidis 220g Pericarpium Citri Reticulatae 220g Rhizoma Pinelliae Preparatum 220g Rhizoma Zingiberis 130g
Poria 130g Massa Medicata Fermentata 130g Fructus Evodiae 130g Fructus Amomi 130g Radix Glycyrrhizae 130g
Said medicine decocts with water twice, and amount of water was not advisable to have powder, decocts 2 hours for the first time, decocted 1 hour for the 2nd time, merge decoction liquor twice, be condensed into extractum, according to the conventional excipients consumption adding medical starch of preparation tablet, mix homogeneously, pelletize, tabletting is made tablet.
Embodiment 4
Rhizoma Atractylodis 270g Rhizoma Coptidis 270g Pericarpium Citri Reticulatae 270g Rhizoma Pinelliae Preparatum 270g Rhizoma Zingiberis 180g
Poria 180g Massa Medicata Fermentata 180g Fructus Evodiae 180g Fructus Amomi 180g Radix Glycyrrhizae 180g
Said medicine is decocted with water twice, and amount of water is 8 times for the first time, decocts 1 hour, and amount of water is 5 times for the second time, decocts half an hour, merges decoction liquor twice, filters, and the adding sweeting agent is an amount of, and oral liquid is made in sterilization.
Embodiment 5
Rhizoma Atractylodis 252g Rhizoma Coptidis 252g Pericarpium Citri Reticulatae 252g Rhizoma Pinelliae Preparatum 252g Rhizoma Zingiberis 168g
Poria 252g Massa Medicata Fermentata 252g Fructus Evodiae 168g Fructus Amomi 168g Radix Glycyrrhizae 168g
(1) Radix Glycyrrhizae of taking-up 1/10 recipe quantity is ground into fine powder, crosses 100 mesh sieves, and is standby;
(2) get Fructus Amomi, Rhizoma Atractylodis, Rhizoma Zingiberis three flavor medicines, add 6 times of water gagings, extract volatile oil, collect.Get volatile oil, double his cyclodextrin, suitable quantity of water is ground, and drying is standby; Distillation gained water liquid filters, and medicinal residues add 6 times of water gagings again and decocted 30 minutes, filter merging filtrate;
(3) get Rhizoma Coptidis, Rhizoma Pinelliae Preparatum, Fructus Evodiae three flavor medicines, add the ethanol of 6 times of amounts 80%, reflux, extract, 3 times, each 1 hour, merge extractive liquid,, decompression recycling ethanol (60～70 ℃ ,-0.08Mpa), get water liquid;
(4) get Pericarpium Citri Reticulatae, Poria, Massa Medicata Fermentata Radix Glycyrrhizae, Poria and add 10 times of water gagings, decoct 2 times, each 1.5 hours, filter, collecting decoction, the filtrate in gained medicinal liquid and the step (2) merges, be concentrated into relative density and be about 1.08 (60 ℃), add ethanol and make and contain alcohol amount and reach 50%, cold preservation 24 hours filters, (60～70 ℃ of decompression recycling ethanols,-0.08Mpa), the water liquid in gained water liquid and the step (3) merges, and being evaporated to relative density is 1.32～1.35 (60 ℃), be blended into the Radix Glycyrrhizae fine powder in the step (1), drying under reduced pressure (60～70 ℃ ,-0.08Mpa), get dry extract;
(5) dried cream powder is broken, crosses 50 mesh sieves, is blended into the betacyclodextrin clathrate in the step (2), and adds starch, and capsule charge is made 1000 of capsules altogether.
Claims (8)
1, a kind of medicine for the treatment of gastritis, peptic ulcer is characterized in that the raw material composition for preparing this medicine is expressed as follows by weight:
Rhizoma Atractylodis 200-300 Rhizoma Coptidis 200-300 Pericarpium Citri Reticulatae 200-300 Rhizoma Pinelliae Preparatum 200-300
Rhizoma Zingiberis 100-200 Poria 200-300 Massa Medicata Fermentata 200-300 Fructus Evodiae 100-200
Fructus Amomi 100-200 Radix Glycyrrhizae 100-200.
2, medicine according to claim 1 is characterized in that the weight ratio of described crude drug is:
Rhizoma Atractylodis 220-270 Rhizoma Coptidis 220-270 Pericarpium Citri Reticulatae 220-270 Rhizoma Pinelliae Preparatum 220-270
Rhizoma Zingiberis 130-180 Poria 130-180 Massa Medicata Fermentata 130-180 Fructus Evodiae 130-180
Fructus Amomi 130-180 Radix Glycyrrhizae 130-180.
3, medicine according to claim 1 is characterized in that the weight ratio of described crude drug is:
Rhizoma Atractylodis 252 Rhizoma Coptidis 252 Pericarpium Citri Reticulataes 252 Rhizoma Pinelliae Preparatum 252 Rhizoma Zingiberiss 168
Poria 252 Massa Medicata Fermentatas 252 Fructus Evodiaes 168 Fructus Amomis 168 Radix Glycyrrhizaes 168.
4,, it is characterized in that raw materials used Rhizoma Atractylodis, Massa Medicata Fermentata are Rhizoma Atractylodis, the Massa Medicata Fermentatas through parched with bran according to the arbitrary described medicine of claim 1-3.
5, according to the described arbitrary medicine of claim 1-3, the dosage form that it is characterized in that this medicine is a kind of in the middle of the pill, tablet, granule, oral liquid, unguentum, capsule, masticatory.
6, the preparation method of the arbitrary described medicine capsule of claim 1-3 is characterized in that this method comprises the steps:
(1) Radix Glycyrrhizae of taking-up 1/10 recipe quantity is ground into fine powder, crosses 100 mesh sieves, and is standby;
(2) get Fructus Amomi, Rhizoma Atractylodis, Rhizoma Zingiberis three flavor medicines, be ground into 10-20 order coarse granule, add 5-7 times of water gaging, be heated to 70-80 ℃, warm macerating 0.5-2 hour, redistillation 2-4 hour, extract volatile oil, collect; Get volatile oil, add 3-5 and doubly measure betacyclodextrin, 6-9 times of water gaging put and ground 20～30 minutes in the colloid mill, takes out pastel, puts 50 ℃ of dryings in the baking oven, and it is standby to cross 60 mesh sieves after pulverizing; Distillation gained water liquid filters, and medicinal residues add 5-7 times of water gaging again and decocted 20-50 minute, filter merging filtrate;
(3) get Rhizoma Coptidis, Rhizoma Pinelliae Preparatum, Fructus Evodiae three flavor medicines, be ground into 10-20 order coarse granule, add the ethanol that 5-7 doubly measures 70-85%, reflux, extract, 2-4 time, each 0.5-2 hour hour, merge extractive liquid,, decompression recycling ethanol gets water liquid:
(4) get Pericarpium Citri Reticulatae, Poria, Massa Medicata Fermentata, Radix Glycyrrhizae four Chinese medicine, Poria powder is broken into 10-20 order coarse granule, add 11-13 times of water gaging, decoct 1-2 time, each 0.5-2 hour, filter, collecting decoction, filtrate in gained medicinal liquid and the step (2) merges, and the relative density that is concentrated into 60 ℃ is about 1.08, adds ethanol and makes and contain the alcohol amount and reach 40-60%, cold preservation 24 hours, filter, decompression recycling ethanol, the water liquid in gained water liquid and the step (3) merges, the relative density that is evaporated to 60 ℃ is 1.32～1.35, be blended into the Radix Glycyrrhizae fine powder in the step (1), drying under reduced pressure gets dry extract;
(5) dried cream powder is broken, crosses 50 mesh sieves, is blended into the betacyclodextrin clathrate in (2), and adds starch adjustment total amount to 330g, and is encapsulated.
7, method according to claim 5 is characterized in that comprising the steps:
(1) Radix Glycyrrhizae of taking-up 1/10 recipe quantity is ground into fine powder, crosses 100 mesh sieves, and is standby;
(2) get Fructus Amomi, Rhizoma Atractylodis, Rhizoma Zingiberis three flavor medicines, be ground into 10-20 order coarse granule, add 6 times of water gagings, be heated to 70-80 ℃, warm macerating 1 hour, redistillation 3 hours extracts volatile oil, collects.Get volatile oil, add 4 times of amount betacyclodextrins, 8 times of water gagings are put and are ground 20～30 minutes in the colloid mill, take out pastel, put 50 ℃ of dryings in the baking oven, and it is standby to cross 60 mesh sieves after pulverizing; Distillation gained water liquid filters, and medicinal residues add 6 times of water gagings again and decocted 30 minutes, filter merging filtrate;
(3) get Rhizoma Coptidis, Rhizoma Pinelliae Preparatum, Fructus Evodiae three flavor medicines, be ground into 10-20 order coarse granule, add the ethanol of 6 times of amounts 80%, reflux, extract, 3 times, each 1 hour, merge extractive liquid,, decompression recycling ethanol gets water liquid;
(4) get Pericarpium Citri Reticulatae, Poria, Massa Medicata Fermentata, Radix Glycyrrhizae four Chinese medicine, Poria powder is broken into 10-20 order coarse granule, add 10 times of water gagings, decoct 2 times, each 1.5 hours, filter, collecting decoction, filtrate in gained medicinal liquid and the step (2) merges, and the relative density that is concentrated into 60 ℃ is about 1.08, adds ethanol and makes and contain the alcohol amount and reach 50%, cold preservation 24 hours, filter, decompression recycling ethanol, the water liquid in gained water liquid and the step (3) merges, the relative density that is evaporated to 60 ℃ is 1.32～1.35, be blended into the Radix Glycyrrhizae fine powder in the step (1), drying under reduced pressure gets dry extract;
Dried cream powder is broken, crosses 50 mesh sieves, is blended into the betacyclodextrin clathrate in the step (2), and adds starch adjustment total amount to 330g, and is encapsulated.
8, according to claim 6 or 7 described methods, the condition that it is characterized in that said decompression recycling ethanol and drying under reduced pressure is 60～70 ℃ ,-0.08Mpa.
Priority Applications (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CN 02159197 CN1239199C (en) | 2002-12-30 | 2002-12-30 | Medicine for treating gastritis and peptic ulcer |
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CN 02159197 CN1239199C (en) | 2002-12-30 | 2002-12-30 | Medicine for treating gastritis and peptic ulcer |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| CN1511552A true CN1511552A (en) | 2004-07-14 |
| CN1239199C CN1239199C (en) | 2006-02-01 |
Family
ID=34237357
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| CN 02159197 Expired - Lifetime CN1239199C (en) | 2002-12-30 | 2002-12-30 | Medicine for treating gastritis and peptic ulcer |
Country Status (1)
| Country | Link |
|---|---|
| CN (1) | CN1239199C (en) |
Cited By (4)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN101601743B (en) * | 2008-06-10 | 2011-11-23 | 中山大学 | A kind of pharmaceutical composition for treating ulcerative colitis and preparation method thereof |
| CN103495037A (en) * | 2013-10-14 | 2014-01-08 | 解乐业 | Traditional Chinese medicine for treating chronic gastritis and peptic ulcer disease caused by helicobacter pylori infection |
| CN114984177A (en) * | 2022-06-17 | 2022-09-02 | 遵义医科大学珠海校区 | Application of dried ginger in preparation of helicobacter pylori urease inhibitor |
| CN118453791A (en) * | 2022-08-17 | 2024-08-09 | 江苏中雍红瑞制药有限公司 | Traditional Chinese medicine composition for treating gastric ulcer and preparation method and application thereof |
-
2002
- 2002-12-30 CN CN 02159197 patent/CN1239199C/en not_active Expired - Lifetime
Cited By (5)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN101601743B (en) * | 2008-06-10 | 2011-11-23 | 中山大学 | A kind of pharmaceutical composition for treating ulcerative colitis and preparation method thereof |
| CN103495037A (en) * | 2013-10-14 | 2014-01-08 | 解乐业 | Traditional Chinese medicine for treating chronic gastritis and peptic ulcer disease caused by helicobacter pylori infection |
| CN103495037B (en) * | 2013-10-14 | 2015-03-25 | 解乐业 | Traditional Chinese medicine for treating chronic gastritis and peptic ulcer disease caused by helicobacter pylori infection |
| CN114984177A (en) * | 2022-06-17 | 2022-09-02 | 遵义医科大学珠海校区 | Application of dried ginger in preparation of helicobacter pylori urease inhibitor |
| CN118453791A (en) * | 2022-08-17 | 2024-08-09 | 江苏中雍红瑞制药有限公司 | Traditional Chinese medicine composition for treating gastric ulcer and preparation method and application thereof |
Also Published As
| Publication number | Publication date |
|---|---|
| CN1239199C (en) | 2006-02-01 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| CN1039286C (en) | Chinese proprietary medicine for anti old and feeble | |
| CN1203872C (en) | Medicine for curing chronic colitis | |
| CN1239199C (en) | Medicine for treating gastritis and peptic ulcer | |
| CN1191082C (en) | Chinese medicinal composition for treating fatty liver and its preparation method | |
| CN1443073A (en) | Preparation method of composition comprising medicinal herb extract for prevention and treatment of arthritis and said composition | |
| CN1840166A (en) | Wendan decoction modern traditional Chinese medicine oral preparation and production method thereof | |
| CN1194735C (en) | Chinese medicine for treating hyperplasia of mammary glands | |
| CN1197612C (en) | Chinese medicine preparation for treating lithiasis in urinary system and urethral infection, and preparing method thereof | |
| CN1313130C (en) | Medicine composition for treating stomachache, its preparation method and uses | |
| CN1246008C (en) | Chinese medicine preparation for curing acute and chronic rhinitis and its production method | |
| CN101062314A (en) | Medicine for curing gout and its preparing method | |
| CN1290529C (en) | Medicine for treating gout, hyperuricemia and hyperlipemia and preparation method thereof | |
| CN1634463A (en) | Medicine for treating diabetes and production method thereof | |
| CN1589892A (en) | Medicinal composition for treating acute, chronic pharyngolaryngitis and its preparation method | |
| CN100337655C (en) | Medicine preparation for preventing and treating allergic rhinitis and compliance rhinitis | |
| CN1660259A (en) | Chinese traditional medicine for treating imitable bowel syndrome and preparation method | |
| CN1287812C (en) | Medicine for treating chronic nephritis and its preparing process | |
| CN1220515C (en) | Medicine for treating throat disease | |
| CN1602945A (en) | Rhinitis treating soft medicinal capsule and preparation process thereof | |
| CN1813819A (en) | Hedgehog hydnum fruiting body or hyphostroma and culture extract and formulation and preparing method | |
| CN100335090C (en) | Medicinal composition for tonifying kidney and eliminating obstruction, and its preparing method | |
| CN101036741A (en) | Medicine for treating cancer and preparing method therefor | |
| CN1201797C (en) | Medicine for treating gastritis and preparation process thereof | |
| CN1562114A (en) | Medicine for treating chronic prostatitis and its preparing method | |
| CN1483429A (en) | Medicine for treat hyperlipemia |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| C06 | Publication | ||
| PB01 | Publication | ||
| C10 | Entry into substantive examination | ||
| SE01 | Entry into force of request for substantive examination | ||
| C14 | Grant of patent or utility model | ||
| GR01 | Patent grant | ||
| EE01 | Entry into force of recordation of patent licensing contract |
Assignee: BEIJING KAIRUI INNOVATION PHARMACEUTICAL TECHNOLOGY CO.,LTD. Assignor: Zhang Hong Contract fulfillment period: 2008.11.25 to 2022.11.24 Contract record no.: 2009990000519 Denomination of invention: Medicine for treating gastritis and peptic ulcer Granted publication date: 20060201 License type: Exclusive license Record date: 20090518 |
|
| LIC | Patent licence contract for exploitation submitted for record |
Free format text: EXCLUSIVE LICENSE; TIME LIMIT OF IMPLEMENTING CONTACT: 2008.11.25 TO 2022.11.24; CHANGE OF CONTRACT Name of requester: BEIJING KAIRUI INNOVATION PHARMACEUTICAL TECHNOLOG Effective date: 20090518 |
|
| CX01 | Expiry of patent term |
Granted publication date: 20060201 |
|
| CX01 | Expiry of patent term |